HCW9302 — Regulatory decision
Late 2026
HCW Biologics projects to establish the Recommended Phase 2 Dose by year end 2026Source filing
HCWB biotech catalysts & pipeline
HCW BIOLOGICS INC · Data as of 2026-09-08
Upcoming catalysts
HCW9302 — Topline data
Q4 2026
With continued patient enrollment, a full Phase 1 human data readout is expected in Q4 2026.Source filing
HCW11-018b — IND submission
H1 2027
We intend to complete IND-enabling studies and submit an IND application to evaluate HCW11-018b, our tetra-valent T-cell engager, in patients with solid tumors in the first half of 2027.Source filing
HCW11-040 — IND submission
H2 2027
The Company intends to file an IND-application to seek authorization to evaluate HCW11-040 in bronchopulmonary dysplasia, a chronic lung disease primarily affecting premature infants, in the second half of 2027, and an IND-application to seek authorization to evaluate HCW11-040 in bronchopulmonary dysplasia, a chronic lung disease primarily affecting premature infants, in the second half of 2027.Source filing